{
    "nct_id": "NCT03402659",
    "title": "A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2021-09-28",
    "description_brief": "This is a phase 2b, double-blind, placebo controlled proof-of-concept study of a an oral small molecule selective inhibitor of p38 alpha kinase, neflamapimod, administered for 24 weeks in subjects with mild Alzheimer's disease. The primary objective is to demonstrate significant improvement relative to placebo-treatment in episodic memory function, as assessed by the Hopkins Verbal Learning Test. Secondary endpoints include Clinical Dementia Rating scale (CDR), Wechsler Memory Scale (WMS), Mini-Mental-Status-Examination (MMSE) and Cerebrospinal fluid (CSF) biomarkers of AD disease activity and progression.",
    "description_detailed": "Details provided elsewhere.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "Placebo Arm",
                    "description": "Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo"
                },
                {
                    "id": "FG001",
                    "title": "Neflamapimod Arm",
                    "description": "Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug)."
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "83"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "78"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "78"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "73"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "5"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "5"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Placebo Arm",
                    "description": "Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo"
                },
                {
                    "id": "BG001",
                    "title": "Neflamapimod Arm",
                    "description": "Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug)."
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "83"
                        },
                        {
                            "groupId": "BG001",
                            "value": "78"
                        },
                        {
                            "groupId": "BG002",
                            "value": "161"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Categorical",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "<=18 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Between 18 and 65 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "14"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "16"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "30"
                                        }
                                    ]
                                },
                                {
                                    "title": ">=65 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "69"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "62"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "131"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "FULL_RANGE",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "72.6",
                                            "lowerLimit": "56",
                                            "upperLimit": "85"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "70.8",
                                            "lowerLimit": "56",
                                            "upperLimit": "84"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "71.8",
                                            "lowerLimit": "56",
                                            "upperLimit": "85"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "43"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "37"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "80"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "40"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "41"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "81"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "American Indian or Alaska Native",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Asian",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "2"
                                        }
                                    ]
                                },
                                {
                                    "title": "Native Hawaiian or Other Pacific Islander",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Black or African American",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "3"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "3"
                                        }
                                    ]
                                },
                                {
                                    "title": "White",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "79"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "77"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "156"
                                        }
                                    ]
                                },
                                {
                                    "title": "More than one race",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Region of Enrollment",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "classes": [
                        {
                            "title": "Netherlands",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "10"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "10"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "20"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "United States",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "38"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "35"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "73"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Czechia",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "3"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "9"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Denmark",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "3"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "7"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "United Kingdom",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "29"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "52"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Weight",
                    "paramType": "MEAN",
                    "dispersionType": "FULL_RANGE",
                    "unitOfMeasure": "Kg",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "74.4",
                                            "lowerLimit": "45",
                                            "upperLimit": "111"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "75.6",
                                            "lowerLimit": "48.9",
                                            "upperLimit": "161"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "75",
                                            "lowerLimit": "45",
                                            "upperLimit": "161"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Total and Delayed Recall on the Hopkins Verbal Learning Test - Revised (HVLT-R)",
                    "description": "Combined change from baseline in z-scores of total and delayed recall on the Hopkins Verbal Learning Test - Revised (HVLT-R) in neflamapimod-treated subjects compared to placebo. The primary endpoint was analyzed using Mixed Model for Repeated Measures (MMRM) with fixed effects for treatment, background AD-specific therapy, CDR-Global Score of 0.5 versus 1.0, scheduled visit (nominal) and scheduled visit by treatment interaction, random effect for subject and baseline Z-score as a covariate.\n\nFor baseline total and delayed recall, a z-score for each subject is defined by z=(x-m)/s where x is the subject's recall at baseline, and m and s are the overall mean and overall standard deviation of recall at baseline across all subjects. A composite baseline z-score for each subject is calculated using equal weighting in the following way: Z=0.5\\*z-score for total recall at baseline + 0.5\\*z-score for delayed recall at baseline. For HVLT-R, higher score indicates improvement.",
                    "populationDescription": "All participants who had analyzable results at Baseline and Week 24",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Z-score",
                    "timeFrame": "Baseline and 24 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo Arm",
                            "description": "Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Neflamapimod Arm",
                            "description": "Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "72"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "71"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.09679",
                                            "spread": "0.074840"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.15776",
                                            "spread": "0.085805"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Mean change from baseline neflamapimod vs placebo",
                            "nonInferiorityType": "OTHER",
                            "pValue": "0.564",
                            "statisticalMethod": "Mixed Models Analysis",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.06098",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.26973",
                            "ciUpperLimit": "0.14777",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.105548"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Wechsler Memory Scale (WMS) Immediate and Delayed Recall",
                    "description": "Change from baseline in Wechsler Memory Scale(WMS) immediate and delayed recall composites in neflamapimod-treated subjects compared to placebo. WMS scores were analyzed using Mixed Model for Repeated Measures (MMRM) with fixed effects for treatment, background AD-specific therapy, CDR-Global Score of 0.5 versus 1.0, scheduled visit (nominal) and scheduled visit by treatment interaction, random effect for subject and baseline Z-score as a covariate. Composite scores for immediate and delayed recall are the combination of all immediate and delayed recall task raw scores and ranges from 0-228. A higher score indicates improvement.\n\nThe following tests in WMS are done both for immediate and delayed recall: Logical Memory test, in which subject is read a story; Verbal-Paired Associates, in which subject is given pairs of words and asked remember which words go together; and Visual Reproduction, in which subject is given drawings of specific shapes",
                    "populationDescription": "All participants who had analyzable results at Baseline and Week 24",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline and 24 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo Arm",
                            "description": "Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Neflamapimod Arm",
                            "description": "Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "77"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "71"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "16.6",
                                            "spread": "2.09"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "16.0",
                                            "spread": "2.07"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Mean change from baseline neflamapimod vs placebo",
                            "nonInferiorityType": "OTHER",
                            "pValue": "0.823",
                            "statisticalMethod": "Mixed Models Analysis",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.6",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-6.0",
                            "ciUpperLimit": "4.8",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "2.72"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)",
                    "description": "Change from baseline in total score of Clinical Dementia Rating Scale - Sum of Boxes (range 0-18) in neflamapimod-treated subjects compared to placebo. CDR-SB scores were analyzed using Mixed Model for Repeated Measures (MMRM) with fixed effects for treatment, background AD-specific therapy, CDR-Global Score of 0.5 versus 1.0, scheduled visit (nominal) and scheduled visit by treatment interaction, random effect for subject and baseline Z-score as a covariate. CDR-SB score is calculated by adding the individual scores from 6 domains, Memory, Orientation, Judgement and Problem Solving, Community Affairs, Home and Hobbies, and Personal Care. CDR-SB scores range from 0-18, where a lower score indicates improvement. The scale is administered in a semi-structured interview format with both the patient and the caregiver/informant.",
                    "populationDescription": "All participants who had analyzable results at Baseline and Week 24",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline and 24 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo Arm",
                            "description": "Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Neflamapimod Arm",
                            "description": "Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "78"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "74"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.0",
                                            "spread": "0.20"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1.1",
                                            "spread": "0.21"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Mean change from baseline neflamapimod vs placebo",
                            "nonInferiorityType": "OTHER",
                            "pValue": "0.806",
                            "statisticalMethod": "Mixed Models Analysis",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.1",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.4",
                            "ciUpperLimit": "0.6",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.25"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Mini-Mental State Examination (MMSE)",
                    "description": "Changes from baseline in Mini-Mental State Examination (MMSE) scores were compared using an ANCOVA with treatment group, background AD-specific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value. The MMSE is scored from 0-30 with a higher score indicating improvement. The MMSE includes questions that test orientation, attention, memory, language and visual-spatial skills.",
                    "populationDescription": "All participants who had analyzable results at Baseline and Follow-up Visit (2 weeks post-treatment)",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline and 26 Weeks (Follow-up visit, 2 weeks from end of dosing)",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo Arm",
                            "description": "Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Neflamapimod Arm",
                            "description": "Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "79"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "70"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.5",
                                            "spread": "0.31"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.8",
                                            "spread": "0.33"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Mean change from baseline neflamapimod vs placebo",
                            "nonInferiorityType": "OTHER",
                            "pValue": "0.489",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.3",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-1.0",
                            "ciUpperLimit": "0.5",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.39"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Cerebrospinal Fluid Total Tau",
                    "description": "Change from, baseline in Total Tau (t-tau) were compared using an ANCOVA with treatment group, background ADspecific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value.",
                    "populationDescription": "All participants with analyzable results at Baseline and Week 24",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "pg/mL",
                    "timeFrame": "Baseline and 24 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo Arm",
                            "description": "Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Neflamapimod Arm",
                            "description": "Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "68"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "62"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "10.0",
                                            "spread": "6.83"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-8.6",
                                            "spread": "7.36"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Mean change from baseline neflamapimod vs placebo",
                            "nonInferiorityType": "OTHER",
                            "pValue": "0.031",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-18.8",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-35.8",
                            "ciUpperLimit": "-1.8",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "8.60"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Cerebrospinal Fluid Phospho-tau",
                    "description": "Change from baseline in Phospho-Tau (p-tau181) were compared using an ANCOVA with treatment group, background AD-specific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value.",
                    "populationDescription": "All participants who had analyzable results at Baseline and Week 24",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "pg/mL",
                    "timeFrame": "Baseline and 24 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo Arm",
                            "description": "Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Neflamapimod Arm",
                            "description": "Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "68"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "62"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.9",
                                            "spread": "0.63"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.1",
                                            "spread": "0.68"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Mean change from baseline neflamapimod vs placebo",
                            "nonInferiorityType": "OTHER",
                            "pValue": "0.012",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-2.0",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-3.6",
                            "ciUpperLimit": "-0.5",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.79"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Cerebrospinal Fluid Amyloid Beta 1-40",
                    "description": "Change from baseline in Amyloid beta (AB1-40) were compared using an ANCOVA with treatment group, background AD-specific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value.",
                    "populationDescription": "All participants who had analyzable results at Baseline and Week 24",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "pg/mL",
                    "timeFrame": "Baseline and 24 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo Arm",
                            "description": "Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Neflamapimod Arm",
                            "description": "Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "68"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "62"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "399.7",
                                            "spread": "249.18"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "282.3",
                                            "spread": "268.58"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Mean change from baseline neflamapimod vs placebo",
                            "nonInferiorityType": "OTHER",
                            "pValue": "0.709",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-117.4",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-738.9",
                            "ciUpperLimit": "504.2",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "314"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Cerebrospinal Fluid Amyloid Beta 1-42",
                    "description": "Change from baseline in Amyloid beta (AB1-42) were compared using an ANCOVA with treatment group, background AD-specific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value.",
                    "populationDescription": "All participants who had analyzable results at Baseline and Week 24",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "pg/mL",
                    "timeFrame": "Baseline and 24 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo Arm",
                            "description": "Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Neflamapimod Arm",
                            "description": "Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "68"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "62"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "31.1",
                                            "spread": "12.70"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "10.0",
                                            "spread": "13.75"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Mean change from baseline neflamapimod vs placebo",
                            "nonInferiorityType": "OTHER",
                            "pValue": "0.192",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-21.0",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-52.7",
                            "ciUpperLimit": "10.7",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "16.03"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Cerebrospinal Fluid Neurogranin",
                    "description": "Change from baseline in Neurogranin were compared using an ANCOVA with treatment group, background ADspecific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value.",
                    "populationDescription": "All participants with analyzable results at Baseline and Week 24",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "pg/mL",
                    "timeFrame": "Baseline and 24 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo Arm",
                            "description": "Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Neflamapimod Arm",
                            "description": "Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "68"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "62"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "11.1",
                                            "spread": "9.16"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-9.9",
                                            "spread": "9.82"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Mean change from baseline neflamapimod vs placebo",
                            "nonInferiorityType": "OTHER",
                            "pValue": "0.068",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-21.0",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-43.6",
                            "ciUpperLimit": "1.6",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "11.43"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Cerebrospinal Fluid Neurofilament Light Chain",
                    "description": "Change from baseline in Neurofilament Light Chain (NFL) were compared using an ANCOVA with treatment group, background AD-specific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value.",
                    "populationDescription": "All participants with analyzable results at Baseline and Week 24",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "pg/mL",
                    "timeFrame": "Baseline and 24 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo Arm",
                            "description": "Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Neflamapimod Arm",
                            "description": "Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "68"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "62"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "231.9",
                                            "spread": "61.31"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "121.7",
                                            "spread": "66.92"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Mean change from baseline neflamapimod vs placebo",
                            "nonInferiorityType": "OTHER",
                            "pValue": "0.156",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-110.1",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-262.7",
                            "ciUpperLimit": "42.4",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "77.11"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Cerebrospinal Fluid P-tau/AB1-42 Ratio",
                    "description": "Changes in the ratio of Phospho-Tau/Amyloid Beta (p-tau181/AB1-42) were compared using an ANCOVA with treatment group, background AD-specific therapy, CDR-Global Score as main effects and the baseline assessment as the covariate. The results of the ANCOVA are summarized using the treatment groups' least square means, the difference between the treatment groups' least square means, the 95% confidence interval for the treatment group difference and the p-value.",
                    "populationDescription": "All participants with analyzable results at Baseline and Week 24",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "ratio",
                    "timeFrame": "Baseline and 24 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo Arm",
                            "description": "Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo"
                        },
                        {
                            "id": "OG001",
                            "title": "Neflamapimod Arm",
                            "description": "Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "68"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "62"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.0",
                                            "spread": "0"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.0",
                                            "spread": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Mean change from baseline neflamapimod vs placebo",
                            "nonInferiorityType": "OTHER",
                            "pValue": "0.590",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.0",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.0",
                            "ciUpperLimit": "0.0",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0"
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "timeFrame": "Up to 29 weeks. AEs occurring from when the subject signed the ICF until up to 30 days after the last dose were collected. Any AEs occurring before the start of treatment (i.e., before the first dose of the investigational product) were recorded in the medical history.",
            "description": "Any sign, symptom, or disease present before starting the treatment period were only considered AEs if they worsen after starting the treatment period.",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Placebo Arm",
                    "description": "Arm of trial including the 83 subjects that were randomly assigned (1:1) to take placebo",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 83,
                    "seriousNumAffected": 3,
                    "seriousNumAtRisk": 83,
                    "otherNumAffected": 16,
                    "otherNumAtRisk": 83
                },
                {
                    "id": "EG001",
                    "title": "Neflamapimod Arm",
                    "description": "Arm of trial including the 78 subjects that were randomly assigned (1:1) to take neflamapimod (active study drug).",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 78,
                    "seriousNumAffected": 2,
                    "seriousNumAtRisk": 78,
                    "otherNumAffected": 18,
                    "otherNumAtRisk": 78
                }
            ],
            "seriousEvents": [
                {
                    "term": "Multiple Myeloma",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "notes": "Multiple Myeloma occurred in one subject. It was not considered related to neflamapimod.",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 83
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Hypokalemia",
                    "organSystem": "Metabolism and nutrition disorders",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "notes": "One SAE of Hypokalemia was reported. It was considered not related to neflamapimod.",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 83
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Non-Cardiac Chest Pain",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 83
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Pneumonia",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 83
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Fall",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 83
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 78
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Upper Respiratory Tract Infection",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 8,
                            "numAffected": 7,
                            "numAtRisk": 83
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Fall",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 83
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 5,
                            "numAffected": 5,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Headache",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 6,
                            "numAffected": 4,
                            "numAtRisk": 83
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 6,
                            "numAffected": 5,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Diarrhea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 83
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 78
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictiveAgreement": false
            },
            "pointOfContact": {
                "title": "Jennifer Conway, Associate Director of Clinical Development",
                "organization": "EIP Pharma",
                "email": "jconway@eippharma.com",
                "phone": "(617) 744-4400"
            }
        }
    },
    "target_category": "disease-targeted small molecule",
    "drug": [
        "neflamapimod (VX-745) \u2014 oral selective p38\u03b1 (p38 MAPK alpha) kinase inhibitor"
    ],
    "placebo": [
        "matching placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests neflamapimod, described as an oral selective p38\u03b1 (p38 MAPK alpha) kinase inhibitor. This is a small\u2011molecule enzyme inhibitor that targets a molecular mechanism (p38\u03b1-mediated synaptic dysfunction and downstream tau phosphorylation) implicated in AD pathology, and the study measures CSF AD biomarkers (T-tau, p-tau181, A\u03b2) in addition to episodic memory. These facts indicate a drug aimed at disease biology rather than solely symptomatic cognitive enhancement. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Act: Key extracted details \u2014 drug name and type: neflamapimod (also previously code-named VX-745), an oral selective p38\u03b1 MAPK small-molecule inhibitor. Trial details: phase 2b, randomized double-blind placebo-controlled, 24 weeks, primary endpoint episodic memory (HVLT), secondary endpoints include CDR, WMS, MMSE and CSF biomarkers. The published trial report shows no clinical benefit at the tested dose but a reduction in CSF T-tau and p-tau181, consistent with on-target biological effects. \ue200cite\ue202turn0search1\ue202turn0search2\ue201",
        "Reflect: Classification check \u2014 although the primary clinical endpoint is cognitive (episodic memory), the mechanism is inhibition of a disease-relevant kinase with downstream effects on tau and synaptic biomarkers, and the agent is a small molecule. Therefore the most appropriate category is 'disease-targeted small molecule' rather than 'cognitive enhancer' or 'neuropsychiatric symptom improvement.' Supporting references confirming mechanism, development history (VX-745 \u2192 neflamapimod), and the phase 2b trial are cited. \ue200cite\ue202turn0search4\ue202turn0search1\ue201",
        "Web search results used: PubMed summary describing neflamapimod as a selective p38\u03b1 inhibitor and its rationale in AD (VX-745 / neflamapimod). \ue200cite\ue202turn0search0\ue201; Full text (PMC) of the phase 2, double-blind, placebo-controlled 24\u2011week study (REVERSE\u2011SD) with endpoints and CSF biomarker results. \ue200cite\ue202turn0search1\ue201; PubMed phase 2 results summary and ClinicalTrials.gov identifier (NCT03402659). \ue200cite\ue202turn0search2\ue201; Discovery paper on VX-745 chemistry and selectivity. \ue200cite\ue202turn0search4\ue201"
    ],
    "agent_type": "B) Tau",
    "explanation_agent": [
        "Reason: The investigational drug is neflamapimod (VX-745), a selective small-molecule p38\u03b1 (p38 MAPK alpha) kinase inhibitor that, in the AD context, is intended to reduce p38\u03b1-mediated synaptic dysfunction and downstream tau phosphorylation \u2014 i.e., its anticipated disease effect is on tau pathology and synaptic dysfunction rather than solely symptomatic neurotransmitter modulation. \ue200cite\ue202turn0search0\ue202turn0search2\ue201",
        "Act: Key extracted details \u2014 drug: neflamapimod (VX-745), oral selective p38\u03b1 MAPK inhibitor; trial: randomized double\u2011blind placebo\u2011controlled 24\u2011week Phase 2 in mild AD (REVERSE\u2011SD, NCT03402659); main finding: no clinical benefit on the primary episodic\u2011memory endpoint at the tested dose, but significant reductions in CSF T\u2011tau and p\u2011tau181 consistent with on\u2011target effects on tau phosphorylation. Based on the mechanism (inhibiting a kinase that promotes tau phosphorylation) and the biomarker changes, the most specific CADRO mapping is to B) Tau. \ue200cite\ue202turn0search1\ue202turn0search3\ue201",
        "Reflect: p38\u03b1 is a kinase involved in inflammatory/stress signaling but in the AD literature its inhibition is pursued to prevent tau phosphorylation and synaptic dysfunction; because the trial\u2019s intended disease biology and observed biomarker effects directly implicate tau pathology (reduced T\u2011tau and p\u2011tau181), the classification as B) Tau is the most specific and appropriate CADRO category rather than a broader inflammation category. If one emphasized the kinase/inflammatory signaling role instead of downstream tau effects, F) Inflammation could be considered, but given the trial rationale and biomarker readouts, B) Tau is the best fit. \ue200cite\ue202turn0search2\ue202turn0search4\ue201",
        "Web search results used (key sources):",
        "- Neflamapimod described as a phase\u20112\u2011ready selective p38\u03b1 inhibitor developed for reversing synaptic dysfunction in early AD. \ue200cite\ue202turn0search0\ue201",
        "- Full text (REVERSE\u2011SD) phase 2, randomized, double\u2011blind, placebo\u2011controlled 24\u2011week study reporting no clinical improvement at the tested dose but significant reductions in CSF T\u2011tau and p\u2011tau181 with neflamapimod. \ue200cite\ue202turn0search1\ue202turn0search3\ue201",
        "- PubMed record / abstract summarizing the REVERSE\u2011SD trial and its outcomes (NCT03402659). \ue200cite\ue202turn0search2\ue201",
        "- Discovery/chemistry paper describing VX\u2011745 (neflamapimod) as a selective p38\u03b1 inhibitor with preclinical anti\u2011inflammatory activity. \ue200cite\ue202turn0search4\ue201"
    ]
}